Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

PURPOSE: To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. METHODS: Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chadha, Awalpreet S., Skinner, Heath D., Gunther, Jillian R., Munsell, Mark F., Das, Prajnan, Minsky, Bruce D., Delclos, Marc E., Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K., Katz, Matthew H., Fleming, Jason B., Javle, Milind M., Wolff, Robert A., Varadhachary, Gauri R., Crane, Christopher H., Krishnan, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919049/
https://www.ncbi.nlm.nih.gov/pubmed/27336466
http://dx.doi.org/10.1371/journal.pone.0156910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919049/
https://www.ncbi.nlm.nih.gov/pubmed/27336466
http://dx.doi.org/10.1371/journal.pone.0156910

Ejemplares similares